C5 (UK) will be holding its 11th International Forum on Pharma Patent Lifecycles on June 20-21, 2012 in London, England. The conference will provide practical and strategic guidance on patent lifecycle extensions, including:
• Recent SPC case law developments and their implications on the industry;
• Maximizing exclusivity for new medical products in light of regulatory and case law developments;
• How to get the most value out of pediatric exclusivity for your patent portfolio;
• Patent Office insights on key challenges in SPC regulation Europe-wide;
• Guidance from the European Commission on lifecycle extensions and anti-trust enforcement;
• Avoiding 'Abuse of Dominance' in your patent management strategies;
• Designing successful patent lifecycle plans for biosimilars following new regulatory guidelines in Europe and the U.S.;
• How U.S. patent reform and U.S. case law developments will impact your lifecycle management strategies; and
• Understanding the latest regulatory developments and IP reforms in Brazil.
In particular, C5 faculty will offer presentations on the following topics:
• EPO -- An Update on the Latest Developments -- to be presented by Dieter Tzschoppe, Director Pure and Applied Organic Chemistry, European Patent Office;
• PTO Panel: Addressing Key Challenges in SPC Regulation Europe-wide and Contrasting Different Interpretations -- panel includes Martijn de Lange, Netherlands Patent Office; Dr. Hubertus Zink, Patent Examiner, DPMA (German Patent and Trademark Office); and Dr. Lawrence Cullen, Deputy Director (Biotechnology, Pharmaceuticals & Organic Chemistry) Patents Directorate, Intellectual Property Office (UK IPO);
• Defining "New Actives" in Light of the Latest Regulatory and Case Law Developments;
• Clarifying SPCs for Enantiomers;
• Utilising Paediatric Exclusivity to Maximise the Value of your Patent Portfolio;
• Big Pharma Panel: How to Adopt SPC Strategies to Overcome Challenges Based on Recent Court Decisions and Industry Trends;
• Developing Strategies for Biosimilar Products Following New Regulatory Guidelines;
• Generics Panel: Strategies for Overcoming IP Challenges for Generic Companies;
• European Commission Keynote: The Latest Guidance on Patent Lifecycle Extensions -- to be presented by Lavinia Teodorescu, DG Competition Antitrust Pharma and Health Services, European Commission;
• Competition Law vs. Patent Law – Overcoming Potential Conflicts;
• Avoiding 'Abuse of Dominance' in Your Patent Management Strategies: Lessons to be Learnt From Recent Cases;
• Prior Art and Obviousness: Understanding this Complicated Legal Area;
• Maximising the Use of Your Existing IP through Patent Pooling;
• Identifying the Latest Amendments and Reforms in Brazilian Patent Law;
• How the Latest IP Trends and Case Law Developments Impact Your Patents in China;
• Discover the Latest on the FDA Guidelines for Biosimilars; and
• The Impact of the U.S. Patent Reform.
A pre-conference workshop, entitled "Designing an Effective and Up-to-date SPC Strategy" will be offered from 1:30 pm to 5:30 pm on June 19, 2012.
A complete brochure for this conference, including an agenda, list of speakers, detailed descriptions of conference sessions, and registration form can be downloaded here.
The registration fee is £2095 for the conference and workshop and £1595 for the conference alone. Those registering by May 22, 2012 will receive a £100 discount. Patent Docs readers who reference the discount code "PD 10" will receive 10% off the current price tier when registering. Those interested in registering for the conference can do so here, by calling +44 20 7878 6888, by faxing a registration form to +44 20 7878 6885, or by e-mailing [email protected].
Patent Docs is a media partner of C5's Pharma Patent Lifecycles conference.
Comments